Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer

키워드

참고문헌 (30)

1. Gazdar AF, "Epidermal growth factor receptor inhibition in lung cancer : the evolving role of individualized therapy", Cancer Metastasis Rev, 29, pp.37~48 (2010)
2. Lynch TJ, "Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib", N Engl J Med, 350, pp.2129~2139 (2004)
3. Paez JG, "EGFR mutations in lung cancer : correlation with clinical response to gefitinib therapy", Science, 304, pp.1497~1500 (2004)
4. Mitsudomi T, "Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor(WJTOG3405) : an open label, randomised phase 3 trial", Lancet Oncol, 11, pp.121~128 (2010)
5. Maemondo M, "Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR", N Engl J Med, 362, pp.2380~2388 (2010)
6. Rosell R, "Erlotinib versus standard chemotherapy as firstline treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer(EURTAC) : a multicentre, open-label, randomised phase 3 trial", Lancet Oncol, 13, pp.239~246 (2012)
7. Zhou C, "Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-smallcell lung cancer(OPTIMAL, CTONG-0802) : a multicentre, open-label, randomised, phase 3 study", Lancet Oncol, 12, pp.735~742 (2011)
8. Wu YL, "Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations(LUX-Lung 6) : an open-label, randomised phase 3 trial", Lancet Oncol, 15, pp.213~222 (2014)
9. Lee JK, "Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor : a metaanalysis", JAMA, 311, pp.1430~1437 (2014)
10. Shepherd FA, "Erlotinib in previously treated nonsmall-cell lung cancer", N Engl J Med, 353, pp.123~132 (2005)
11. Han JY, "A randomized phase II study of gefitinib plus simvastatin versus gefitinib alone in previously treated patients with advanced non-small cell lung cancer", Clin Cancer Res, 17, pp.1553~1560 (2011)
12. Cortot AB, "Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas", Eur Respir Rev, 23, pp.356~366 (2014)
13. Endo A, "The discovery and development of HMG-CoA reductase inhibitors", Atheroscler Suppl, 5, pp.67~80 (2004)
14. Seabra MC, "Rab GTPases, intracellular traffic and disease", Trends Mol Med, 8, pp.23~30 (2002)
15. Pruitt K, "Ras and Rho regulation of the cell cycle and oncogenesis", Cancer Lett, 171, pp.1~10 (2001)
16. Mantha AJ, "Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor", Clin Cancer Res, 11, pp.2398~2407 (2005)
17. Park IH, "Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations", Invest New Drugs, 28, pp.791~799 (2010)
18. Prueksaritanont T, "The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6", Br J Clin Pharmacol, 56, pp.120~124 (2003)
19. Peters S, "Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer : comparative pharmacokinetics and drug-drug interactions", Cancer Treat Rev, 40, pp.917~926 (2014)
20. Eisenhauer EA, "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)", Eur J Cancer, 45, pp.228~247 (2009)
21. Lee DH, "Epidermal growth factor receptor status in anaplastic thyroid carcinoma", J Clin Pathol, 60, pp.881~884 (2007)
22. Hirsch FR, "Epidermal growth factor receptor in non-small-cell lung carcinomas : correlation between gene copy number and protein expression and impact on prognosis", J Clin Oncol, 21, pp.3798~3807 (2003)
23. Soria JC, "Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung(LUX-Lung 8) : an open-label randomised controlled phase 3 trial", Lancet Oncol, 16, pp.897~907 (2015)
24. Kudo K, "Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer(NSCLC) : Okayama Lung Cancer Study Group experience", Cancer Chemother Pharmacol, 77, pp.1005~1009 (2016)
25. Lee Y, "High EGFR gene copy number and skin rash as predictive markers for EGFR tyrosine kinase inhibitors in patients with advanced squamous cell lung carcinoma", Clin Cancer Res, 18, pp.1760~1768 (2012)
26. Hata A, "Erlotinib for pretreated squamous cell carcinoma of the lung in Japanese patients", Jpn J Clin Oncol, 41, pp.1366~1372 (2011)
27. Cappuzzo F, "Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer", J Natl Cancer Inst, 97, pp.643~655 (2005)
28. Wong WW, "HMGCoA reductase inhibitors and the malignant cell : the statin family of drugs as triggers of tumor-specific apoptosis", Leukemia, 16, pp.508~519 (2002)
29. Demierre MF, "Statins and cancer prevention", Nat Rev Cancer, 5, pp.930~942 (2005)
30. Lee J, "Effect of simvastatin plus cetuximab", irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab, 2014, pp.32, 535~541

관련 논문AI추천